ZA201400601B - Use of ccne2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors - Google Patents

Use of ccne2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors

Info

Publication number
ZA201400601B
ZA201400601B ZA2014/00601A ZA201400601A ZA201400601B ZA 201400601 B ZA201400601 B ZA 201400601B ZA 2014/00601 A ZA2014/00601 A ZA 2014/00601A ZA 201400601 A ZA201400601 A ZA 201400601A ZA 201400601 B ZA201400601 B ZA 201400601B
Authority
ZA
South Africa
Prior art keywords
ccne2
treatment
cdk inhibitors
breast tumours
novel pan
Prior art date
Application number
ZA2014/00601A
Inventor
Philip Groth
Gerhard Siemeister
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/065947 external-priority patent/WO2013024118A1/en
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of ZA201400601B publication Critical patent/ZA201400601B/en

Links

ZA2014/00601A 2011-08-16 2014-01-24 Use of ccne2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors ZA201400601B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011808991 2011-08-16
PCT/EP2012/065947 WO2013024118A1 (en) 2011-08-16 2012-08-15 Use of ccne2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors

Publications (1)

Publication Number Publication Date
ZA201400601B true ZA201400601B (en) 2015-09-30

Family

ID=60971546

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/00601A ZA201400601B (en) 2011-08-16 2014-01-24 Use of ccne2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors

Country Status (1)

Country Link
ZA (1) ZA201400601B (en)

Similar Documents

Publication Publication Date Title
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
PL3023788T3 (en) Compositions of tumor specific neoantigens for use in treating tumours
GB201120993D0 (en) Novel compounds and their use in therapy
IL239007A0 (en) Use of eribulin in the treatment of breast cancer
GB201004020D0 (en) New therapeutic use
PL2780332T3 (en) Morpholinylbenzotriazines for use in cancer therapy
IL230781A0 (en) Use of ccne2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors
PL2564983T3 (en) Sharpener
EP2717901A4 (en) He4 based therapy for malignant disease
EP2817304A4 (en) Novel compounds and their use in therapy
EP2910948A4 (en) Novel cancer marker and utilization thereof
GB201111630D0 (en) Novel compounds and their use
EP2600896A4 (en) Treating breast cancer with anti-il-19 antibody
IL238453A0 (en) Trans-clomiphene for use in cancer therapy
LT2872176T (en) Carboranylporphyrins for use in the treatment of cancer
HK1198587A1 (en) Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals -2-
GB201106630D0 (en) Cancer therapy
ZA201400601B (en) Use of ccne2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors
HK1196403A1 (en) Use of mad2l2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors mad2l2 pan-cdk
EP2720720A4 (en) Combination therapy to prevent dcis formation and progression to breast cancer
GB201206926D0 (en) Novel compositions having use in therapy
GB201118220D0 (en) Cancer therapy
IL229109A0 (en) Diognosis of cancer
GB201120096D0 (en) Novel therapy